LOAMU
ALXN

Lombard Odier Asset Management (USA)’s Alexion Pharmaceuticals ALXN Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-19,000
Closed -$2.97M – 428
2020
Q4 		$2.97M Buy
+19,000
New +$2.44M 0.14% 146
2013
Q4 		– Sell
-25,000
Closed -$2.9M – 180
2013
Q3 		$2.9M Hold
25,000
– – 0.15% 102
2013
Q2 		$2.31M Buy
+25,000
New +$2.41M 0.13% 121

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s ALXN Position: Q1 2021 in Review

Lombard Odier Asset Management (USA) sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 19,000 shares — an estimated $2.97M sold.

Lombard Odier Asset Management (USA) first reported a position in ALXN in Q2 2013 and held it in 3 quarters. The position peaked at $2.97M in Q4 2020. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Lombard Odier Asset Management (USA) reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 19,000 Alexion Pharmaceuticals shares in Q1 2021, an estimated $2.97M.
  • Lombard Odier Asset Management (USA) first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Lombard Odier Asset Management (USA)'s Alexion Pharmaceuticals position peaked at $2.97M in Q4 2020.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q1 2021, filed 17 May 2021.